Lubiprostone + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Idiopathic Constipation

Conditions

Chronic Idiopathic Constipation

Trial Timeline

Mar 13, 2017 → Aug 17, 2017

NCT ID

NCT03097861

About Lubiprostone + Placebo

Lubiprostone + Placebo is a phase 3 stage product being developed by Mallinckrodt Pharmaceuticals for Chronic Idiopathic Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT03097861. Target conditions include Chronic Idiopathic Constipation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03097861	Phase 3	Completed	Mar 13, 2017	Aug 17, 2017	Chronic Idiopathic Constipation
NCT01298219	Phase 3	Completed	Dec 1, 2010	Nov 1, 2011	Opioid-induced Bowel Dysfunction
NCT00595946	Phase 3	Completed	Aug 1, 2007	Mar 1, 2009	Opioid-Induced Bowel Dysfunction
NCT00597428	Phase 3	Completed	Aug 1, 2007	Mar 1, 2009	Opioid-Induced Bowel Dysfunction
NCT00399542	Phase 3	Completed	May 1, 2005	Jul 1, 2006	Irritable Bowel Syndrome

Competing Products

20 competing products in Chronic Idiopathic Constipation

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Mallinckrodt Pharmaceuticals

Lubiprostone + Lubiprostone + LubiprostoneApproved

Lubiprostone + PlaceboPhase 3